- Home
- GGZ vs ATRA Comparison
GGZ vs ATRA Comparison
Compare GGZ & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GGZ | ATRA |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.4M | 129.4M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | GGZ | ATRA |
|---|---|---|
| Price | $15.04 | $17.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 12.8K | ★ 77.2K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 5.39% | N/A |
| EPS Growth | N/A | N/A |
| EPS | 1.75 | ★ 1.97 |
| Revenue | N/A | ★ $151,930,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $6.79 | $9.15 |
| Revenue Growth | N/A | ★ 51.27 |
| 52 Week Low | $9.43 | $5.01 |
| 52 Week High | $12.50 | $18.95 |
Technical Indicators
Market Signals| Indicator | GGZ | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 69.03 | 62.25 |
| Support Level | $14.75 | $16.59 |
| Resistance Level | $14.95 | $18.30 |
| Average True Range (ATR) | 0.18 | 1.35 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 72.44 | 70.77 |
Price Performance
Historical ComparisonAbout GGZ Gabelli Global Small and Mid Cap Value Trust (The) of Beneficial Interest
The Gabelli Global Small and Mid Cap Value Trust is a diversified closed-ended management investment company whose investment objective is long-term capital growth. It invests in equity securities such as common stock and preferred stock of companies.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).